title: Retinal toxicity in human immunodeficiency virus-infected children treated with 2',3'-dideoxyinosine.
abstract: To assess the safety and antiretroviral activity of 2',3'-dideoxyinosine, we enrolled 43 children with symptomatic (Centers for Disease Control class P-2) human immunodeficiency virus infection in a Phase I-II study and monitored them prospectively for the development of ocular complications secondary to HIV infection or drug toxicity. Follow-up ranged from 12 to 103 weeks with a median follow-up of 71 weeks. Three of 43 children (7.0%) developed peripheral atrophy of the retinal pigment epithelium during treatment with 2',3'-dideoxyinosine. The two children with the most severe retinal atrophy were enrolled in the study at the highest dosage studied (540 mg/m2/day). In contrast to findings in children, no retinal atrophy in HIV-infected adults treated with 2',3'-dideoxyinosine has been evident to date.
authors.affiliation: Laboratory of Immunology, National Eye Institute, National Institutes of Health, Bethesda, MD 20892.
authors.forename: S M
authors.initials: SM
authors.lastname: Whitcup
authors.forename: K M
authors.initials: KM
authors.lastname: Butler
authors.forename: R
authors.initials: R
authors.lastname: Caruso
authors.forename: M D
authors.initials: MD
authors.lastname: de Smet
authors.forename: B
authors.initials: B
authors.lastname: Rubin
authors.forename: R N
authors.initials: RN
authors.lastname: Husson
authors.forename: J S
authors.initials: JS
authors.lastname: Lopez
authors.forename: R
authors.initials: R
authors.lastname: Belfort
authors.forename: P A
authors.initials: PA
authors.lastname: Pizzo
authors.forename: R B
authors.initials: RB
authors.lastname: Nussenblatt
mesh_terms: D001284:Atrophy; D002648:Child; D002675:Child, Preschool; D016049:Didanosine / Q000009:adverse effects* / Q000627:therapeutic use; D004341:Drug Evaluation; D004585:Electrooculography; D004596:Electroretinography; D005260:Female; D005500:Follow-Up Studies; D005654:Fundus Oculi; D015658:HIV Infections / Q000150:complications / Q000188:drug therapy*; D015497:HIV-1; D006801:Humans; D008297:Male; D010857:Pigment Epithelium of Eye / Q000473:pathology; D011446:Prospective Studies; D012160:Retina / Q000473:pathology; D012164:Retinal Diseases / Q000139:chemically induced* / Q000209:etiology; D015215:Zidovudine / Q000627:therapeutic use
chemical_list: D015215:Zidovudine; D016049:Didanosine